Current and Emerging Role of Antibody–Drug Conjugates in HER2-Negative Breast Cancer
Rachel O. Abelman(Massachusetts General Hospital), Aditya Bardia(Harvard University), Laura M. Spring(Massachusetts General Hospital), Phoebe Ryan(Harvard University), Jennifer C Keenan(Harvard University)
Cited by 4
Related Papers
Mechanisms of Resistance to Antibody–Drug Conjugates
|Cancers|2023|135
Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trial
|Annals of Oncology|2023|75
Letrozole + ribociclib versus letrozole + placebo as neoadjuvant therapy for ER+ breast cancer (FELINE trial).
|Journal of Clinical Oncology|2020|68
Sequential use of antibody-drug conjugate after antibody-drug conjugate for patients with metastatic breast cancer: ADC after ADC (A3) study.
|Journal of Clinical Oncology|2023|53